Nir Naor
Known title: EVP, CFO & TreasurerCIK: 0001982278
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Axogen Receives New Analyst Coverage and Valuation Upside. Axogen has attracted new analyst coverage from Robinhood and B of A Securities, both issuing bullish notes and setting price targets around $52. A Yahoo analysis suggests the stock may be about 26% undervalued on cash‑flow grounds, while the company has fallen 22.6% in the past month. These developments highlight renewed investor interest and potential upside relative to recent price action.
Transaction History
| STIM | ▲ Buy | Grant | 500,000 | $0 | 7/23/2026 | View on chart |
| AXGN | ▼ Sell | Tax Withholding | 39,132 | $596K | 1/6/2025 | View on chart |
| AXGN | ▲ Buy | Grant | 300,000 | — | 1/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
STIM shifts focus from devices to psychedelic infrastructure
Neuronetics announced it is moving away from solely manufacturing its TMS device and is building a platform to support psychedelic therapies. The change aims to broaden the company's role in the emerging mental-health market. The stock is currently trading near its $1.19 support level and has an RSI of 25.4, indicating a low momentum environment.
STIM shifts focus from devices to psychedelic infrastructure. Neuronetics announced it is moving away from solely manufacturing its TMS device and is building a platform to support psychedelic therapies. The change aims to broaden the company's role in the emerging mental-health market. The stock is currently trading near its $1.19 support level and has an RSI of 25.4, indicating a low momentum environment.